Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Symptomatic intracerebral hemorrhage in proximal and distal medium middle cerebral artery occlusion patients treated with mechanical thrombectomy
Yedavalli, Vivek , Salim, Hamza , Musmar, Basel , Adeeb, Nimer, Essibayi, Muhammed Amir , Naamani, Kareem El , Henninger, Nils , Sundararajan, Sri Hari , Kuhn, Anna Luisa, Khalife, Jane, Tan, Benjamin YQ, Heit, Jeremy J. , Regenhardt, Robert W, Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A, Puri, Ajit S, Dyzmann, Christian , Colasurdo, Marco , Barreau, Xavier, Renieri, Leonardo, Filipe, Joo Pedro, Harker, Pablo, Marotta, Thomas R. , Spears, Julian, Jabbour, Pascal , Biswas, Arundhati , Clarenon, Frdric, Varela, Ricardo, Baker, Amanda, Altschul, David , Gonzalez, Nestor R. , Mhlenbruch, Markus A, Costalat, Vincent, Gory, Benjamin, Stracke, Paul, Aziz-Sultan, Mohammad Ali, Shaikh, Hamza , Liebeskind, David S. , Pedicelli, Alessandro, Alexandre, Andrea M, Tancredi, Illario, Faizy, Tobias D, Kalsoum, Erwah, Lubicz, Boris, Patel, Aman B, Guenego, Adrien , Regenhardt, Robert W. , Tan, Benjamin Yong‐Qiang , Varela, Ricardo , Alexandre, Andrea , Pulli, Benjamin , Yedavalli, Vivek S , Salim, Hamza , ElNaamani, Kareem , Ghozy, Sherief , Scarcia, Luca , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Colasurdo, Marco , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Shaikh, Hamza A , Liebeskind, David S. , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Essibayi, Muhammed Amir , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Pulli, Benjamin , Varela, Ricardo , Adeeb, Nimer , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Bernstock, Joshua D. , Fiehler, Jens , Sheth, Sunil A , Puri, Ajit S , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Spears, Julian , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Baker, Amanda, Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | July 8, 2024 | Volume: 17 | Issue: 8 | Pages: 803-810

10.1136/jnis-2024-021879 | PMID 38977305 Get It

Background Acute ischemic stroke (AIS) caused by distal medium vessel occlusions (DMVOs) represents a significant proportion of overall stroke cases. While intravenous thrombolysis (IVT) has been a primary treatment, advancements in endovascular procedures have led to increased use of mechanical thrombectomy (MT) in DMVO stroke patients. However, symptomatic intracerebral hemorrhage (sICH) remains a critical complication of AIS, particularly after undergoing intervention. This study aims to identify factors associated with sICH in DMVO stroke patients undergoing MT. Methods This retrospective analysis utilized data from the Multicenter Analysis of Distal Medium Vessel Occlusions: Effect of Mechanical Thrombectomy (MAD-MT) registry, involving 37 centers across North America, Asia, and Europe. Middle cerebral artery (MCA) DMVO stroke patients were included. The primary outcome measured was sICH, as defined per the Heidelberg Bleeding Classification. Univariable and multivariable logistic regression were used to identify factors independently associated with sICH. Results Among 1708 DMVO stroke patients, 148 (8.7%) developed sICH. Factors associated with sICH in DMVO patients treated with MT included older age (adjusted odds ratio (aOR) 1.01, 95% confidence interval (95% CI) 1.00 to 1.03, P=0.048), distal occlusion site (M3, M4) compared with medium occlusions (M2) (aOR 1.71, 95% CI 1.07 to 2.74, P=0.026), prior use of antiplatelet drugs (aOR 2.06, 95% CI 1.41 to 2.99, P<0.001), lower Alberta Stroke Program Early CT Scores (ASPECTS) (aOR 0.75, 95% CI 0.66 to 0.84, P<0.001), higher preoperative blood glucose level (aOR 1.00, 95% CI 1.00 to 1.01, P=0.012), number of passes (aOR 1.27, 95% CI 1.15 to 1.39, P<0.001), and successful recanalization (Thrombolysis In Cerebral Infarction (TICI) 2b-3) (aOR 0.43, 95% CI 0.28 to 0.66, P<0.001). Conclusion This study provides novel insight into factors associated with sICH in patients undergoing MT for DMVO, emphasizing the importance of age, distal occlusion site, prior use of antiplatelet drugs, lower ASPECTS, higher preoperative blood glucose level, and procedural factors such as the number of passes and successful recanalization. Pending confirmation, consideration of these factors may improve personalized treatment strategies.
Predicting Response to Neuromodulators or Prokinetics in Patients With Suspected Gastroparesis Using Machine Learning: The “BMI, Infectious Prodrome, Delayed GES, and No Diabetes” Model
Takakura, Will , Surjanhata, Brian , McCallum, Richard W. , Schulman, Michael I., Wo, John M. , Sarosiek, Irene , Moshiree, Baha , Lee, Allen , Hasler, William L. , Lee, Allen A , Nguyen, Linda Anh B. , Parkman, Henry P. , Rao, Satish S.C. , Kuo, Braden

Mayo Clinic

Clinical and Translational Gastroenterology | July 8, 2024 | Volume: 15 | Issue: 9 | Pages: e1

10.14309/ctg.0000000000000743 | PMID 39320959 Get It

INTRODUCTION: Pharmacologic therapies for symptoms of gastroparesis (GP) have limited efficacy, and it is difficult to predict which patients will respond. In this study, we implemented a machine learning model to predict the response to prokinetics and/or neuromodulators in patients with GP-like symptoms. METHODS: Subjects with suspected GP underwent simultaneous gastric emptying scintigraphy (GES) and wireless motility capsule and were followed for 6 months. Subjects were included if they were started on neuromodulators and/or prokinetics. Subjects were considered responders if their GP Cardinal Symptom Index at 6 months decreased by ≥1 from baseline. A machine learning model was trained using lasso regression, ridge regression, or random forest. Five-fold cross-validation was used to train the models, and the area under the receiver operator characteristic curve (AUC-ROC) was calculated using the test set. RESULTS: Of the 150 patients enrolled, 123 patients received either a prokinetic and/or a neuromodulator. Of the 123, 45 were considered responders and 78 were nonresponders. A ridge regression model with the variables, such as body mass index, infectious prodrome, delayed gastric emptying scintigraphy, no diabetes, had the highest AUC-ROC of 0.72. The model performed well for subjects on prokinetics without neuromodulators (AUC-ROC of 0.83) but poorly for those on neuromodulators without prokinetics. A separate model with gastric emptying time, duodenal motility index, no diabetes, and functional dyspepsia performed better (AUC-ROC of 0.75). DISCUSSION: This machine learning model has an acceptable accuracy in predicting those who will respond to neuromodulators and/or prokinetics. If validated, our model provides valuable data in predicting treatment outcomes in patients with GP-like symptoms.
Ex-situ machine perfusion in clinical liver transplantation: Current practices and future directions
Nguyen, Michelle , Li, Xingjie , Linares, Natalia M., Moss, Adyr A. , Reddy, Kunam S. , Mathur, Amit K. , Nguyen, Michelle C , Linares, Natalia, Jadlowiec, Caroline , Mathur, Amit , Jadlowiec, Caroline C.

Mayo Clinic

Liver Transplantation | July 5, 2024 | Volume: 31 | Issue: 4 | Pages: 531-544

10.1097/lvt.0000000000000428 | PMID 38967460 Get It

Ex-situ machine perfusion of the liver has surmounted traditional limitations associated with static cold storage in the context of organ preservation. This innovative technology has changed the landscape of liver transplantation by mitigating ischemia perfusion injury, offering a platform for continuous assessment of organ quality, and providing an avenue for optimizing the use of traditionally marginal allografts. This review summarizes the contemporary clinical applications of machine perfusion devices and discusses potential future strategies for real-time viability assessment, therapeutic interventions, and modulation of organ function after recovery.
Features of Importance in Nasal Endoscopy: Deriving a Meaningful Framework
Babahaji, Layla M., Ganeshan, Vinayak , Nguyen, Thinh S., Ahmed, Omar G. , Barton, Blair M. , Halawi, Akaber, Joe, Stephanie, Marino, Michael J. , Patel, Zara M. , Rangarajan, Sanjeet V., Riley, Charles A. , Roxbury, Christopher R. , Tabaee, Abtin, Tang, Dennis M. , Wu, Arthur W. , Yim, Michael , Bidwell, Jonathan, Riley, Charles A. , McCoul, Edward D , Patel, Zara , Wu, Arthur W , Chandra, Rakesh Kumar , Chen, Philip G. , Gudis, David A. , Higgins, Thomas S , Kuan, Edward C , Ramakrishnan, Vijay R , McCoul, Edward D.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 5, 2024 | Volume: 171 | Issue: 4 | Pages: 1052-1061

10.1002/ohn.889 | PMID 38967295 Get It

AbstractObjectiveCritical components of the nasal endoscopic examination have not been definitively established for either the normal examination or for clinical disorders. This study aimed to identify concordance among rhinologists regarding the importance of examination findings for various nasal pathologies.Study DesignA consortium of 19 expert rhinologists across the United States was asked to rank the importance of findings on nasal endoscopy for 5 different sinonasal symptom presentations.SettingAn online questionnaire was distributed in July 2023.MethodsThe questionnaire utilized JotForm® software and featured 5 cases with a set of 4 identical questions per case, each covering a common indication for nasal endoscopy. Rankings were synthesized into Normalized Attention Scores (NASs) and Weighted Normalized Attention Scores (W‐NASs) to represent the perceived importance of each feature, scaled from 0 to 1.ResultsGeneral concordance was found for examination findings on nasal endoscopy within each case. The perceived features of importance differed between cases based on clinical presentation. For instance, in evaluating postnasal drip, the middle meatus was selected as the most important structure to examine (NAS, 0.73), with mucus selected as the most important abnormal finding (W‐NAS, 0.66). The primary feature of interest for mucus was whether it was purulent or not (W‐NAS, 0.67). Similar analyses were performed for features in each case.ConclusionThe implicit framework existing among rhinologists may help standardize examinations and improve diagnostic accuracy, augment the instruction of trainees, and inform the development of artificially intelligent algorithms to enhance clinical decision‐making during nasal endoscopy.
Creation and Validation of a Novel 3-Dimensional Pediatric Hip Ultrasound Model
Nichols, Francesca R. , Nguyen, Mylinh T., Ekpenyong, Atim, Pade, Kathryn , Skinner, John A. , Ryan, Justin , Skinner, John Andrew , Morris, Jonathan M. , Nguyen, Mylinh T.

Mayo Clinic

Pediatric Emergency Care | July 1, 2024 | Volume: 40 | Issue: 9 | Pages: e216-e220

10.1097/pec.0000000000003155 | PMID 38950383 Get It

Objectives The aim of this study was to create and validate a 3-dimensional (3D) ultrasound model with normal and abnormal pediatric hip joint anatomy that is comparable to a pediatric hip joint in appearance and anatomy and replicates sonographic characteristics of a pediatric hip joint. Methods A 3D rendering of the bone and soft tissue was created from a computed tomography pelvic scan of a pediatric patient. This rendering was modified to include a unilateral joint effusion. The bone was 3D printed with a photopolymer plastic, whereas the soft tissue was cast with a silicone mixture in a 3D-printed mold. The effusion was simulated by injecting saline into the soft tissue cavity surrounding the bone. The ultrasound model was validated by pediatric point-of-care ultrasonographers at an international pediatric ultrasound conference. Results A pediatric hip ultrasound model was developed that simulates both normal and abnormal pediatric hip joint anatomy, each with an appropriately sized, measurable joint effusion. Validation by pediatric point-of-care ultrasonographers showed that the key aspects of a normal pediatric hip joint (femoral physis, sloped femoral neck, and adequate soft tissue) with an identifiable and measurable effusion were included in the ultrasound model. Conclusions In this study, we successfully created a cost-effective, reusable, and reproducible 3D pediatric hip ultrasound model. The majority of pediatric point-of-care ultrasonographers who evaluated the model agreed that this model is comparable to a pediatric patient for the purpose of teaching ultrasound skills and joint space measurement.
Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH).
Talukder, Rafee , Hobeika, Charbel, Johnson, Jeffrey S. , Castaneda, D.H. Marmolejo , Zakopoulou, Roubini , Hui, Gavin , Buznego, Lucía Andrea Alonso , Stewart, Tyler F. , Grivas, Petros , Bakaloudi, Dimitra Rafailia , Makrakis, Dimitrios , Diamantopoulos, Leonidas Nikolaos , Jindal, Tanya , Nguyen, Charles B. , Hobeika, Charbel S. , Thomas, Vinay Mathew , Korolewicz, James , Barata, Pedro C. , Brown, Jason R. , Epstein, Ilana Bensussen , Khaki, Ali Raza

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4580-4580

10.1200/jco.2024.42.16_suppl.4580 Get It

4580 Background: ICIs are used for UC in different settings. Most cases have pure urothelial carcinoma (PUC) but about a third have UC mixed with SH. We examined pts with UC treated with ICI and hypothesized that outcomes would not differ between PUC and mixed with SH. Methods: We retrospectively included pts with PUC and any SH component treated with ICI as adjuvant, 1st line [1L] upfront, maintenance avelumab [mAV], ≥2nd line [2+L] therapy; pts were divided by SH type. Pts with multiple SH were included as separate group. We excluded pts with pure non-UC histology and pts treated with neoadjuvant ICI. We calculated overall response rate (ORR), median overall, progression-free and disease-free survival [mOS, mPFS, mDFS] using KM method from ICI start. Analysis was stratified by therapy line; multivariable models were adjusted by Khaki factors for 1L/upfront, mAV and Bellmunt factors for 2+L; reference group was PUC. We used descriptive statistics for small subsets. Results: We included 1525 pts from 26 sites; n=752 1L, n=609 2+L; 76% men, 80% White, 69% smoking history, 80% lower urinary tract primary, 28% SH. Median f/u time from 1L ICI start 24 months (mo): mPFS was 3 (95%CI 2.8-3.2) mo for PUC (n=340), 3 (95%CI 2-4) mo for squamous (n=60) (HR=1, [95%CI 0.7-1.4]), 2 (95%CI 1.4-3.2) mo for micropapillary (n=36) (HR=1.3 [95% 0.9-2]) and 4 (3.5-4.5) mo for ≥2 SH (n=20) (HR=0.9 [95%CI 0.6-1.5]). Median f/u time from 2+L ICI start 26 mo: mPFS was 3 (95%CI 2.4-3.2) mo for PUC (n=264), 4 (95%CI 2-5) mo for squamous (n=33) (HR=0.8, [95%CI 0.6-1.2]), 3 (95%CI 1.6-3.7) mo for micropapillary (n=17) (HR=0.9 [95% 0.6-1.7]) and 3 (2.5-3.1) mo for ≥2 SH (n=10) (HR=1.2 [95%CI 0.6-2.2]); Table shows ORR/OS data. Data on adjuvant and mAV settings will also be presented. Conclusions: We found no significant survival difference between PUC and SH. ORR was numerically higher with sarcomatoid SH and ≥2 SH in the 1L upfront setting. Limitations: retrospective design, small sample size in a few subsets, lack of randomization and central scan/path (% SH) review, selection bias, unmeasured confounders. [Table: see text]
Addressing Disparities in Pediatric Congenital Heart Disease: A Call for Equitable Health Care
Chowdhury, Devyani , Elliott, Pietro , Asaki, S. Yukiko , Amdani, Shahnawaz , Nguyen, Quang‐Tuyen , Ronai, Christina , Tierney, Seda , Levy, Victor Y. , Puri, Kriti , Altman, Carolyn A. , Johnson, Jonathan N. , Glickstein, Julie S. , Elliott, Pietro , Ronai, Christina

Mayo Clinic

Journal of the American Heart Association | June 27, 2024 | Volume: 13 | Issue: 13 | Pages: No page available

10.1161/jaha.123.032415 | PMID 38934870 Get It

While significant progress has been made in reducing disparities within the US health care system, notable gaps remain. This article explores existing disparities within pediatric congenital heart disease care. Congenital heart disease, the most common birth defect and a leading cause of infant death, has garnered substantial attention, revealing certain disparities within the US health care system. Factors such as race, ethnicity, insurance coverage, socioeconomic status, and geographic location are all commonalities that significantly affect health disparities in pediatric congenital heart disease. This comprehensive review sheds light on disparities from diverse perspectives in pediatric care, demonstrates the inequities and inequalities leading to these disparities, presents effective solutions, and issues a call to action for providers, institutions, and the health care system. Recognizing and addressing these disparities is imperative for ensuring equitable care and enhancing the long‐term well‐being of children affected by congenital heart disease. Implementing robust, evidence‐based frameworks that promote responsible and safe interventions is fundamental to enduring change.
Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function.
Patell, Kanchi , Naleid, Nikolas , Storandt, Michael H. , Zemla, Tyler , Gile, Jennifer , Tran, Nguyen H. , Chakrabarti, Sakti , Jin, Zhaohui , Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4099-4099

10.1200/jco.2024.42.16_suppl.4099 Get It

4099 Background: A+B is standard of care for advanced HCC in the first line setting, although was only evaluated in patients with CP class A liver function in IMbrave150. We sought to determine outcomes of patients in the real-world setting. Methods: We conducted a multi-institution retrospective analysis of patients with HCC who received A+B as first-line systemic therapy between March 2018 and November 2023, at Mayo Clinic and University Hospitals Seidman Cancer Center. Treatment response was evaluated, and progression free survival (PFS) and overall survival (OS) were determined using the Kaplan Meier method. Multivariate analyses were performed using Cox proportional hazard regression method. Results: Among patients with HCC (n=322), 226, 86, and 10 had CP-A, -B, and -C liver function, while 120, 177, and 25 had ALBI grade 1, 2, and 3 liver function. Median age was 66.5 years, 78.6% were male, and 82.6% were white. Liver disease causes included hepatitis B (5.3%) and C (34.8%), ethanol use (26.1%), and non-alcoholic steatohepatitis (15.5%). Macrovascular invasion was seen in 42.9%, and 30.4% had extrahepatic metastatic disease. Median OS for patients with CP-A5/6 was 21.6 months, B7 (n=49) was 9.1 months, and B8-C12 was 4.7 months ( p<0.0001). Median OS by ALBI grade was 34.9, 11.7, and 4.7 months for grades 1, 2, and 3. Median PFS was 8.9, 6.4, and 2.7 months for CP-A5/6, B7, and B8-C12 ( p<0.0001). Median PFS by ALBI grade was 11.0, 6.4, and 3.7 months for grades 1, 2, and 3 ( p=0.0001). Among patients with CP-A, those with ALBI grade 1 had mOS of 34.9 months versus 14.2 months for those with grade 2. Partial response was seen in 29.2%, 19.8% and 10.0% of patients with CP-A, -B, and -C, while 32.7%, 33.7%, and 40.0% had stable disease. In a univariate analysis, factors predictive of shorter OS included CP-B7 or CP-B8-C12, ALBI grade 2 or 3, hepatitis B, poorer ECOG performance status (PS), macrovascular invasion, non-white race, and lack of prior surgery or embolization. In multivariate analyses, CP score, ALBI grade, hepatitis B, ECOG PS, and macrovascular invasion were significantly associated with survival. There was significant interaction between CP and ALBI grade (Table). Conclusions: A+B remains a viable option in patients with CP-B7 liver function, although benefit is significantly less than those with CP-A. ALBI score has predictive value and can identify two prognostic groups among those with CP-A liver function. [Table: see text]
Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents
Williams, Michelle D. , Liu, Zhiyan , Bychkov, Andrey , Baloch, Zubair, Chiosea, Simion L, Erkılıç, Suna , Fridman, M. , Harahap, Agnes Stephanie , Kakudo, Kennichi, Khalil, Moosa, Khanafshar, Elham, Kumarasinghe, Priyanthi , Lloyd, Ricardo V., Nguyen, Truong Phan-Xuan , Ocal, Idris Tolgay, Prasad, Manju L. , Rana, Chanchal , Sajed, Dipti P. , Seethala, Raja R. , LiVolsi, Virginia A. , Bychkov, Andrey , Jung, Chan Kwon , Rana, Chanchal , Nikiforov, Yuri , Rossi, Esther Diana , Agarwal, Shipra , Ryska, Ales , Ghuzlan, Abir Al , Baloch, Zubair , Chernock, Rebecca , Chiosea, Simion, Cipriani, Nicole A. , Hang, Jen‐Fan , Pusztaszeri, Marc , Sadow, Peter M. , Tallini, Giovanni , Vuong, Huy Gia , Yeğen, Gülçin , Nikiforov, Yuri E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 12, 2024 | Volume: 110 | Issue: 1 | Pages: 166-175

10.1210/clinem/dgae354 | PMID 38874075 Get It

Abstract Context Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced as a new entity replacing the diagnosis of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC). Significant variability in the incidence of NIFTP diagnosed in different world regions has been reported. Objective To investigate the rate of adoption of NIFTP, change in practice patterns, and uniformity in applying diagnostic criteria among pathologists practicing in different regions. Methods Two surveys distributed to pathologists of the International Endocrine Pathology Discussion Group with multiple-choice questions on NIFTP adoption into pathology practice and whole slide images of 5 tumors to collect information on nuclear score and diagnosis. Forty-eight endocrine pathologists, including 24 from North America, 8 from Europe, and 16 from Asia/Oceania completed the first survey and 38 the second survey. Results A 94% adoption rate of NIFTP by the pathologists was found. Yet, the frequency of rendering NIFTP diagnosis was significantly higher in North America than in other regions (P = .009). While the highest concordance was found in diagnosing lesions with mildly or well-developed PTC-like nuclei, there was significant variability in nuclear scoring and diagnosing NIFTP for tumors with moderate nuclear changes (nuclear score 2) (case 2, P &lt; .05). Pathologists practicing in North America and Europe showed a tendency for lower thresholds for PTC-like nuclei and NIFTP than those practicing in Asia/Oceania. Conclusion Despite a high adoption rate of NIFTP across geographic regions, NIFTP is diagnosed more often by pathologists in North America. Significant differences remain in diagnosing intermediate PTC-like nuclei and respectively NIFTP, with more conservative nuclear scoring in Asia/Oceania, which may explain the geographic differences in NIFTP incidence.
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
Yonemori, Kan , Banda, Kalyan , Sohn, Joohyuk , Lombard, Janine , Bender, Laura , Uribe, Bernard Doger de Spéville, Dizon, Don S. , García-Corbacho, Javier, Li, Yujia , Nguyen, Bastien , Ismail‐Khan, Roohi , Neven, P., Sohn, Joohyuk , Boni, Valentina , Meniawy, Tarek M. , Kaufman, Peter A. , Richardson, Debra L. , Matsumoto, Koji , Giridhar, Karthik V. , García-Sáenz, José Á. , Prenen, Hans

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 5589-5589

10.1200/jco.2024.42.16_suppl.5589 Get It

5589 Background: Imlunestrant is a next-generation oral SERD designed to deliver continuous estrogen receptor (ER) target inhibition aimed to improve outcomes for patients (pts) with ER+ cancers. In the first-in-human Phase 1a/1b EMBER trial (NCT04188548), imlunestrant showed favorable safety, pharmacokinetics, and clinical benefit in pre-treated pts with ER+ advanced breast cancer or EEC. Here, we report updated imlunestrant monotherapy data and the first clinical data of imlunestrant + abemaciclib in ER+ EEC pts from EMBER. Methods: Eligible pts had ER+ EEC previously treated with (or deemed inappropriate for) platinum-containing chemotherapy. Prior fulvestrant or aromatase inhibitor therapy was not allowed. In Phase 1a, pts received imlunestrant alone, and in Phase 1b, pts were randomized (1:1) to imlunestrant alone or with abemaciclib. Plasma samples were collected at baseline (all pts) and at cycle 2 (monotherapy pts) for ctDNA analysis (Guardant 360 assay) to correlate with clinical benefit. Primary endpoints were RP2D of imlunestrant monotherapy and in combination. Secondary endpoints included safety, tolerability, and overall response rate (ORR), clinical benefit rate (CBR: complete or partial response, or stable disease ≥24 weeks), and progression-free survival (PFS) using RECIST v1.1. Results: Overall, 72 pts were treated; 39 pts received monotherapy (33 at 400mg [RP2D] and 6 at 800mg po daily) and 33 pts received imlunestrant (29 at 400mg and 4 at 800mg po daily) + abemaciclib (150mg po twice daily). Baseline characteristics, safety, and preliminary efficacy are presented (Table). For monotherapy, the most common TEAEs (all grade/grade 3) were nausea (36%/3%), diarrhea (26%/0), urinary tract infection (26%/3%), and abdominal pain (21%/8%). For imlunestrant + abemaciclib, the most common TEAEs (all grade/grade 3) were diarrhea (88%/3%), nausea (67%/0), fatigue (49%/9%) and anemia (46%/12%). In the monotherapy arm, pts with deeper (≥ 50%) declines in ctDNA variant allele frequency had a higher CBR (4/7 vs 4/17). Conclusions: Imlunestrant, as monotherapy or with abemaciclib, appears safe and tolerable with preliminary evidence of efficacy in pts with metastatic ER+ EEC. Clinical trial information: NCT04188548 . [Table: see text]